Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report

Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report

Inactivation of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene is considerably more frequent in squamous cell lung cancer (SqCLC) than in other subtypes of lung cancer and may be a promising target for this histology. Here, we present the course of diagnosis and treatment of a patient with a...

Full description

Bibliographic Details
Main Authors: Douglas Dias e Silva, Guilherme Bes Borba, Juliana Rodrigues Beal, Gehan Botrus, Akemi Osawa, Sérgio Eduardo Alonso Araújo, Fernando Moura, Rafael Aliosha Kaliks Guendelmann, Pedro Luiz Serrano Uson Junior
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:International Journal of Molecular Sciences
Subjects:
squamous cell lung cancer
lung cancer
nivolumab
ipilimumab
checkpoint inhibition therapy
abemaciclib
Online Access:https://www.mdpi.com/1422-0067/24/4/4209

Internet

https://www.mdpi.com/1422-0067/24/4/4209

Similar Items